Selecta Biosciences (SELB) Tops Q1 EPS by 34c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
Selecta Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
May 5, 2022 7:30 AM EDTPhase 1 trial of SEL-302 remains on track to initiate in the second half of 2022
DISSOLVE I & II studies on track for completion in Q4 2022 with joint topline readout in Q1 2023
Completed underwritten offering, raising approximately $38.7 million in gross proceeds, extending runway into mid-2024
As of April 11, 2022, Selecta had approximately $154.2 million in cash, cash equivalents, restricted cash and marketable securities
Selecta to host conference call today at 8:30 AM ET
WATERTOWN, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a... More
